Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by AMI Asset Management Corp

AMI Asset Management Corp trimmed its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 23.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,460 shares of the biopharmaceutical company's stock after selling 11,484 shares during the quarter. AMI Asset Management Corp's holdings in Halozyme Therapeutics were worth $1,791,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of HALO. Envestnet Asset Management Inc. grew its holdings in shares of Halozyme Therapeutics by 4.9% in the second quarter. Envestnet Asset Management Inc. now owns 229,620 shares of the biopharmaceutical company's stock worth $12,023,000 after purchasing an additional 10,651 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Halozyme Therapeutics by 12.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company's stock worth $99,363,000 after acquiring an additional 209,530 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new position in Halozyme Therapeutics in the 2nd quarter worth about $182,000. Vanguard Personalized Indexing Management LLC increased its position in shares of Halozyme Therapeutics by 13.5% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 20,711 shares of the biopharmaceutical company's stock worth $1,084,000 after acquiring an additional 2,463 shares during the period. Finally, Intech Investment Management LLC bought a new stake in shares of Halozyme Therapeutics during the second quarter valued at approximately $1,192,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO traded up $1.14 during trading on Tuesday, hitting $55.94. The stock had a trading volume of 1,203,499 shares, compared to its average volume of 1,621,977. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 12-month low of $33.15 and a 12-month high of $65.53. The stock has a market capitalization of $7.12 billion, a price-to-earnings ratio of 18.52, a price-to-earnings-growth ratio of 0.42 and a beta of 1.24. The stock has a 50-day simple moving average of $49.50 and a two-hundred day simple moving average of $54.14.

Insider Buying and Selling

In other news, Director Jeffrey William Henderson sold 10,000 shares of the company's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now owns 43,611 shares in the company, valued at $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 2.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

HALO has been the topic of several research analyst reports. Piper Sandler increased their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. HC Wainwright raised their target price on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the company a "buy" rating in a research note on Friday, January 10th. Cowen reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Wells Fargo & Company lowered their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Finally, JMP Securities increased their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a research note on Friday, November 1st. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $60.89.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.